Hangzhou, China, September 12, 2024 — The recombinant humanized anti-EGFR-CD3 enzyme-controlled bispecific antibody (hereinafter referred to as CMDE005), developed by Centrymed based on its proprietary dual-antibody platform, proBiTE, has been approved for clinical trials by the NMPA for the treatment of various EGFR-positive advanced solid tumors. As the pharmaceutical research collaborator for the IND application of the CMDE005 project, HJB congratulates the approval of this project for clinical trials.

HANGZHOU, CHINA - On January 26, 2024, HJB announced a breakthrough in its Highly Intensified Continuous Bioprocessing (HiCB) platform. By leveraging the in-house developed cell culture medium, ExcelPro CHOTM, HiCB has achieved an impressive maximum daily output of 8 g/L-day in intensified continuous perfusion, over a tenfold increase in productivity when compared to same cell line in traditional fed-batch platform. 

HANGZHOU, CHINA - On November 06, 2023, HJB announced a new strategic partnership with Hangzhou Apextide Bio-pharmaceutical Technology Company Limited (hereinafter referred to as "Apextide"). This strategic partnership will pursue the marketing and promotion of the APIs and DP manufacturing of oligonucleotide.

On 27th April, SynerK, an innovative biopharmaceutical company focusing on developing RNA-targeted therapeutics, announced that its Phase I clinical trial of the first small interfering RNA (siRNA) product under research has been completed with the first subject enrolled for dosing. Public data shows that this is the first domestic siRNA candidate drug against a specific target, which is involved in the clinical administration and treatment phase in subjects. SynerK owns the completely independent intellectual property right.

Small interfering RNA (siRNA) drugs, as a hotspot in the development of small nucleic acid-based drugs, have been widely used for their high gene silencing efficiency, controllable adverse effects, and easy synthesis. Recently, HJB has also embraced the first siRNA formulation filling project, which was commissioned by SynerK, a leading company in siRNA technology, for the development of siRNA formulation prescriptions and filling work. During the project, the two parties cooperated and gave full play to SynerK's experience in the development and production of siRNA formulations and to HJB's experience in the development and filling of injectable liquid formulations. The technical team of HJB overcame many technical difficulties and challenges of siRNA formulation and completed the first batch of filling in one go, with a filling yield as high as 95%.

HJB congratulates its partner BioneCure for receiving IND approval for BIO-106.

HJB congratulates its client on an approval of CMC process change supplemental application filed to  NMPA in support of a late phase clinical trial in China.